

Trial objectives of SELECT

Added to SoC* in patients with established CVD and overweight/obesity...

Primary objective

Demonstrate that semaglutide s.c. 2.4 mg OW lowers the incidence of MACE vs placebo



Secondary objectives

Compare the effect of semaglutide 2.4 mg OW to placebo for

- Mortality
- CV risk factors
- Glucose metabolism
- Body weight
- Renal function



Exploratory objectives

Compare the effect of semaglutide 2.4 mg OW to placebo for

- Smoking status
- Hospitalizations



**CV risk reduction standard of care*

Three-component MACE consisted of non-fatal MI, non-fatal stroke, CV death.

CVD, cardiovascular disease; MACE, major adverse cardiovascular events; OW, once weekly; SELECT, semaglutide effects on cardiovascular outcomes in people with overweight or obesity; SoC, standard of care.